Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults

References

• World Health Organization. 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008; 83:373 - 84; PMID: 18927997
   PubMedGoogle Scholar
• Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1:CD000422; PMID: 23440780
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012; 30:6802 - 8; http://dx.doi.org/10.1016/j.vaccine.2012.09.019; PMID: 23000122
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59:1102 - 6; PMID: 20814406
   PubMedGoogle Scholar
• Ada G. Vaccines and vaccination. N Engl J Med 2001; 345:1042 - 53; http://dx.doi.org/10.1056/NEJMra011223; PMID: 11586958
   PubMed Web of Science ®Google Scholar
• Clutterbuck EA, Oh S, Hamaluba M, Westcar S, Beverley PC, Pollard AJ. Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine. Clin Vaccine Immunol 2008; 15:182 - 93; http://dx.doi.org/10.1128/CVI.00336-07; PMID: 18032593
   PubMed Web of Science ®Google Scholar
• Clutterbuck EA, Lazarus R, Yu LM, Bowman J, Bateman EA, Diggle L, Angus B, Peto TE, Beverley PC, Mant D, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012; 205:1408 - 16; http://dx.doi.org/10.1093/infdis/jis212; PMID: 22457293
   PubMed Web of Science ®Google Scholar
• Klugman KP, Black S, Dagan R, Malley R, Whitney CG. Pneumococcal conjugate vaccine and pneumococcal common protein vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. China: Saunders; 2012. p. 504-41.
   Google Scholar
• Lockhart SP, Hackell JG, Fritzell B. Pneumococcal conjugate vaccines: emerging clinical information and its implications. Expert Rev Vaccines 2006; 5:553 - 64; http://dx.doi.org/10.1586/14760584.5.4.553; PMID: 16989635
   PubMed Web of Science ®Google Scholar
• Lockhart S, Watson W, Fletcher P, Leeper A, Edwards S, McCaughey M, Dunning A, Sikkema D, Siber G. Aluminum Phosphate is an Active Adjuvant for CRM197 Pneumococcal Conjugate Vaccine (PnC) in Infants. Eighth Annual Conference on Vaccine Research. Baltimore, Maryland, USA; May 8-11, 2005. [Abstract P4] Available at: http://www.nfid.org/professional-education/archives/acvr/acvr05.pdf. Accessed on January 6, 2014.
   Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31:3577 - 84; http://dx.doi.org/10.1016/j.vaccine.2013.04.085; PMID: 23688526
   PubMed Web of Science ®Google Scholar
• Lee LH, Frasch CE, Falk LA, Klein DL, Deal CD. Correlates of immunity for pneumococcal conjugate vaccines. Vaccine 2003; 21:2190 - 6; http://dx.doi.org/10.1016/S0264-410X(03)00025-2; PMID: 12706710
   PubMed Web of Science ®Google Scholar
• Jackson LA. Pneumococcal polysaccharide vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. China: Saunders; 2012. p. 542-72.
   Google Scholar
• Greenberg RN, Gurtman A, Frenck R, Strout CB, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber W, Schmoele-Thoma B. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal-vaccine naïve adults 60–64 years of age. Vaccine 2013; Forthcoming
   Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013; 31:3594 - 602; http://dx.doi.org/10.1016/j.vaccine.2013.04.084; PMID: 23688525
   PubMed Web of Science ®Google Scholar
• de Roux A, Schmöle-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, Baker SA, Razmpour A, Emini EA, Fernsten PD, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46:1015 - 23; http://dx.doi.org/10.1086/529142; PMID: 18444818
   PubMed Web of Science ®Google Scholar
• Lazarus R, Clutterbuck E, Yu LM, Bowman J, Bateman EA, Diggle L, Angus B, Peto TE, Beverley PC, Mant D, et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis 2011; 52:736 - 42; http://dx.doi.org/10.1093/cid/cir003; PMID: 21367726
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, Pebody R, Miller E. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009; 49:1318 - 25; http://dx.doi.org/10.1086/606046; PMID: 19814624
   PubMed Web of Science ®Google Scholar
• Törling J, Hedlund J, Konradsen HB, Örtqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003; 22:96 - 103; http://dx.doi.org/10.1016/S0264-410X(03)00521-8; PMID: 14604576
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Flamaing J, Rümke HC, Penzes J, Juergens C, Wenz A, Jayawardene D, Giardina P, Emini EA, Gruber WC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine 2011; 29:5195 - 202; http://dx.doi.org/10.1016/j.vaccine.2011.05.031; PMID: 21619909
   PubMed Web of Science ®Google Scholar
• Paradiso PR. Pneumococcal conjugate vaccine for adults: a new paradigm. Clin Infect Dis 2012; 55:259 - 64; http://dx.doi.org/10.1093/cid/cis359; PMID: 22495545
   PubMed Web of Science ®Google Scholar
• Prevnar 13: United States Prescribing Information. Available from: http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm201669.pdf. Accessed on March 6, 2013.
   Google Scholar
• European Medicines Agency. Prevenar 13: Summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001104/WC500057247.pdf. Accessed on March 6, 2014
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816 - 9; PMID: 23051612
   PubMedGoogle Scholar
• Quataert S, Martin D, Anderson P, Giebink GS, Henrichsen J, Leinonen M, Granoff DM, Russell H, Siber G, Faden H, et al. A multi-laboratory evaluation of an enzyme-linked immunoassay quantitating human antibodies to Streptococcus pneumoniae polysaccharides. Immunol Invest 2001; 30:191 - 207; http://dx.doi.org/10.1081/IMM-100105064; PMID: 11570640
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, Keyserling HL, Carlone GM. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997; 4:415 - 22; PMID: 9220157
   PubMedGoogle Scholar
• Hu BT, Yu X, Jones TR, Kirch C, Harris S, Hildreth SW, Madore DV, Quataert SA. Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae.. Clin Diagn Lab Immunol 2005; 12:287 - 95; PMID: 15699424
   PubMedGoogle Scholar
• Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 2011; 29:7207 - 11; http://dx.doi.org/10.1016/j.vaccine.2011.06.056; PMID: 21689707
   PubMed Web of Science ®Google Scholar